Good Hemp, Inc. (GHMP) Stock Competitors & Peer Comparison
See (GHMP) competitors and their performances in Stock Market.
Peer Comparison Table: Beverages - Non-Alcoholic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GHMP | $0.00 | +0.00% | 155.5K | -0.00 | -$0.12 | N/A |
| NNFSF | $5.51 | +0.00% | 62B | 26.24 | $0.21 | +2.62% |
| CCHBF | $58.04 | +4.97% | 21.2B | 19.22 | $3.02 | +2.41% |
| CCHGY | $57.43 | +0.81% | 20.9B | 19.02 | $3.02 | +2.29% |
| EMBVF | $12.05 | -6.47% | 20.5B | 18.83 | $0.64 | +3.87% |
| BTVCY | $29.51 | +0.00% | 7.3B | 23.99 | $1.23 | N/A |
| COCSF | $10.93 | -1.62% | 5.7B | -273.19 | -$0.04 | +3.75% |
| YKLTF | $16.61 | +0.00% | 4.8B | 17.66 | $0.94 | +2.74% |
| YKLTY | $8.01 | -5.49% | 4.7B | 17.04 | $0.47 | +2.35% |
| BTVCF | $16.40 | +15.09% | 4.1B | 26.89 | $0.61 | N/A |
Stock Comparison
GHMP vs NNFSF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, NNFSF has a market cap of 62B. Regarding current trading prices, GHMP is priced at $0.00, while NNFSF trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas NNFSF's P/E ratio is 26.24. In terms of profitability, GHMP's ROE is +0.05%, compared to NNFSF's ROE of +0.44%. Regarding short-term risk, GHMP is less volatile compared to NNFSF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check NNFSF's competition here
GHMP vs CCHBF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, CCHBF has a market cap of 21.2B. Regarding current trading prices, GHMP is priced at $0.00, while CCHBF trades at $58.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas CCHBF's P/E ratio is 19.22. In terms of profitability, GHMP's ROE is +0.05%, compared to CCHBF's ROE of +0.26%. Regarding short-term risk, GHMP is less volatile compared to CCHBF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check CCHBF's competition here
GHMP vs CCHGY Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, CCHGY has a market cap of 20.9B. Regarding current trading prices, GHMP is priced at $0.00, while CCHGY trades at $57.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas CCHGY's P/E ratio is 19.02. In terms of profitability, GHMP's ROE is +0.05%, compared to CCHGY's ROE of +0.26%. Regarding short-term risk, GHMP is less volatile compared to CCHGY. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check CCHGY's competition here
GHMP vs EMBVF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, EMBVF has a market cap of 20.5B. Regarding current trading prices, GHMP is priced at $0.00, while EMBVF trades at $12.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas EMBVF's P/E ratio is 18.83. In terms of profitability, GHMP's ROE is +0.05%, compared to EMBVF's ROE of +0.15%. Regarding short-term risk, GHMP is less volatile compared to EMBVF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check EMBVF's competition here
GHMP vs BTVCY Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, BTVCY has a market cap of 7.3B. Regarding current trading prices, GHMP is priced at $0.00, while BTVCY trades at $29.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas BTVCY's P/E ratio is 23.99. In terms of profitability, GHMP's ROE is +0.05%, compared to BTVCY's ROE of +0.34%. Regarding short-term risk, GHMP and BTVCY have similar daily volatility (0.00).Check BTVCY's competition here
GHMP vs COCSF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, COCSF has a market cap of 5.7B. Regarding current trading prices, GHMP is priced at $0.00, while COCSF trades at $10.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas COCSF's P/E ratio is -273.19. In terms of profitability, GHMP's ROE is +0.05%, compared to COCSF's ROE of +0.16%. Regarding short-term risk, GHMP is less volatile compared to COCSF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check COCSF's competition here
GHMP vs YKLTF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, YKLTF has a market cap of 4.8B. Regarding current trading prices, GHMP is priced at $0.00, while YKLTF trades at $16.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas YKLTF's P/E ratio is 17.66. In terms of profitability, GHMP's ROE is +0.05%, compared to YKLTF's ROE of +0.08%. Regarding short-term risk, GHMP is less volatile compared to YKLTF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check YKLTF's competition here
GHMP vs YKLTY Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, YKLTY has a market cap of 4.7B. Regarding current trading prices, GHMP is priced at $0.00, while YKLTY trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas YKLTY's P/E ratio is 17.04. In terms of profitability, GHMP's ROE is +0.05%, compared to YKLTY's ROE of +0.08%. Regarding short-term risk, GHMP is less volatile compared to YKLTY. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check YKLTY's competition here
GHMP vs BTVCF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, BTVCF has a market cap of 4.1B. Regarding current trading prices, GHMP is priced at $0.00, while BTVCF trades at $16.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas BTVCF's P/E ratio is 26.89. In terms of profitability, GHMP's ROE is +0.05%, compared to BTVCF's ROE of +0.34%. Regarding short-term risk, GHMP is less volatile compared to BTVCF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check BTVCF's competition here
GHMP vs UNPSF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, UNPSF has a market cap of 3.8B. Regarding current trading prices, GHMP is priced at $0.00, while UNPSF trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas UNPSF's P/E ratio is 14.77. In terms of profitability, GHMP's ROE is +0.05%, compared to UNPSF's ROE of +0.15%. Regarding short-term risk, GHMP and UNPSF have similar daily volatility (0.00).Check UNPSF's competition here
GHMP vs CCOJY Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, CCOJY has a market cap of 3.5B. Regarding current trading prices, GHMP is priced at $0.00, while CCOJY trades at $10.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas CCOJY's P/E ratio is -11.35. In terms of profitability, GHMP's ROE is +0.05%, compared to CCOJY's ROE of -0.12%. Regarding short-term risk, GHMP is less volatile compared to CCOJY. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check CCOJY's competition here
GHMP vs ITONF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, ITONF has a market cap of 3.1B. Regarding current trading prices, GHMP is priced at $0.00, while ITONF trades at $14.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas ITONF's P/E ratio is 21.27. In terms of profitability, GHMP's ROE is +0.05%, compared to ITONF's ROE of +0.02%. Regarding short-term risk, GHMP is less volatile compared to ITONF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check ITONF's competition here
GHMP vs CCOJF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, CCOJF has a market cap of 3.1B. Regarding current trading prices, GHMP is priced at $0.00, while CCOJF trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas CCOJF's P/E ratio is 98.11. In terms of profitability, GHMP's ROE is +0.05%, compared to CCOJF's ROE of -0.12%. Regarding short-term risk, GHMP and CCOJF have similar daily volatility (0.00).Check CCOJF's competition here
GHMP vs YNAJF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, YNAJF has a market cap of 2.4B. Regarding current trading prices, GHMP is priced at $0.00, while YNAJF trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas YNAJF's P/E ratio is 19.05. In terms of profitability, GHMP's ROE is +0.05%, compared to YNAJF's ROE of +0.12%. Regarding short-term risk, GHMP is less volatile compared to YNAJF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check YNAJF's competition here
GHMP vs ITOEF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, ITOEF has a market cap of 2.2B. Regarding current trading prices, GHMP is priced at $0.00, while ITOEF trades at $18.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas ITOEF's P/E ratio is 24.13. In terms of profitability, GHMP's ROE is +0.05%, compared to ITOEF's ROE of +0.02%. Regarding short-term risk, GHMP and ITOEF have similar daily volatility (0.00).Check ITOEF's competition here
GHMP vs CHFHY Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, CHFHY has a market cap of 1.3B. Regarding current trading prices, GHMP is priced at $0.00, while CHFHY trades at $9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas CHFHY's P/E ratio is 10.40. In terms of profitability, GHMP's ROE is +0.05%, compared to CHFHY's ROE of +0.13%. Regarding short-term risk, GHMP is less volatile compared to CHFHY. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check CHFHY's competition here
GHMP vs FQVTF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, FQVTF has a market cap of 1.2B. Regarding current trading prices, GHMP is priced at $0.00, while FQVTF trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas FQVTF's P/E ratio is 40.69. In terms of profitability, GHMP's ROE is +0.05%, compared to FQVTF's ROE of +0.09%. Regarding short-term risk, GHMP is less volatile compared to FQVTF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check FQVTF's competition here
GHMP vs LSDAF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, LSDAF has a market cap of 1.1B. Regarding current trading prices, GHMP is priced at $0.00, while LSDAF trades at $160.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas LSDAF's P/E ratio is 12.15. In terms of profitability, GHMP's ROE is +0.05%, compared to LSDAF's ROE of +0.16%. Regarding short-term risk, GHMP and LSDAF have similar daily volatility (0.00).Check LSDAF's competition here
GHMP vs BAGFF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, BAGFF has a market cap of 903.2M. Regarding current trading prices, GHMP is priced at $0.00, while BAGFF trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas BAGFF's P/E ratio is 14.50. In terms of profitability, GHMP's ROE is +0.05%, compared to BAGFF's ROE of +0.14%. Regarding short-term risk, GHMP is less volatile compared to BAGFF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check BAGFF's competition here
GHMP vs NJMVF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, NJMVF has a market cap of 696.4M. Regarding current trading prices, GHMP is priced at $0.00, while NJMVF trades at $19.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas NJMVF's P/E ratio is 106.06. In terms of profitability, GHMP's ROE is +0.05%, compared to NJMVF's ROE of +0.24%. Regarding short-term risk, GHMP and NJMVF have similar daily volatility (0.00).Check NJMVF's competition here
GHMP vs KGKG Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, KGKG has a market cap of 328.3M. Regarding current trading prices, GHMP is priced at $0.00, while KGKG trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas KGKG's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to KGKG's ROE of +0.01%. Regarding short-term risk, GHMP is less volatile compared to KGKG. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check KGKG's competition here
GHMP vs HAATF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, HAATF has a market cap of 194.4M. Regarding current trading prices, GHMP is priced at $0.00, while HAATF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas HAATF's P/E ratio is 9.68. In terms of profitability, GHMP's ROE is +0.05%, compared to HAATF's ROE of +0.11%. Regarding short-term risk, GHMP is less volatile compared to HAATF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check HAATF's competition here
GHMP vs UPCHY Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, UPCHY has a market cap of 43.7M. Regarding current trading prices, GHMP is priced at $0.00, while UPCHY trades at $101.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas UPCHY's P/E ratio is 14.44. In terms of profitability, GHMP's ROE is +0.05%, compared to UPCHY's ROE of +0.15%. Regarding short-term risk, GHMP is less volatile compared to UPCHY. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check UPCHY's competition here
GHMP vs PDPG Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, PDPG has a market cap of 37.3M. Regarding current trading prices, GHMP is priced at $0.00, while PDPG trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas PDPG's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to PDPG's ROE of +0.32%. Regarding short-term risk, GHMP is less volatile compared to PDPG. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check PDPG's competition here
GHMP vs JSDA Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, JSDA has a market cap of 34.4M. Regarding current trading prices, GHMP is priced at $0.00, while JSDA trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas JSDA's P/E ratio is -28.99. In terms of profitability, GHMP's ROE is +0.05%, compared to JSDA's ROE of -0.30%. Regarding short-term risk, GHMP is less volatile compared to JSDA. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check JSDA's competition here
GHMP vs MOJO Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, MOJO has a market cap of 8M. Regarding current trading prices, GHMP is priced at $0.00, while MOJO trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas MOJO's P/E ratio is 42.50. In terms of profitability, GHMP's ROE is +0.05%, compared to MOJO's ROE of +0.24%. Regarding short-term risk, GHMP and MOJO have similar daily volatility (0.00).Check MOJO's competition here
GHMP vs FGHFF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, FGHFF has a market cap of 6.4M. Regarding current trading prices, GHMP is priced at $0.00, while FGHFF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas FGHFF's P/E ratio is -0.07. In terms of profitability, GHMP's ROE is +0.05%, compared to FGHFF's ROE of -4.47%. Regarding short-term risk, GHMP is less volatile compared to FGHFF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check FGHFF's competition here
GHMP vs KRTL Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, KRTL has a market cap of 5.3M. Regarding current trading prices, GHMP is priced at $0.00, while KRTL trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas KRTL's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to KRTL's ROE of -3.20%. Regarding short-term risk, GHMP is less volatile compared to KRTL. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check KRTL's competition here
GHMP vs HIRU Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, HIRU has a market cap of 4.2M. Regarding current trading prices, GHMP is priced at $0.00, while HIRU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas HIRU's P/E ratio is 0.24. In terms of profitability, GHMP's ROE is +0.05%, compared to HIRU's ROE of -0.00%. Regarding short-term risk, GHMP is less volatile compared to HIRU. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check HIRU's competition here
GHMP vs RVBR Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, RVBR has a market cap of 3.6M. Regarding current trading prices, GHMP is priced at $0.00, while RVBR trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas RVBR's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to RVBR's ROE of -2.09%. Regarding short-term risk, GHMP and RVBR have similar daily volatility (0.00).Check RVBR's competition here
GHMP vs OSOPF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, OSOPF has a market cap of 2.4M. Regarding current trading prices, GHMP is priced at $0.00, while OSOPF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas OSOPF's P/E ratio is 0.02. In terms of profitability, GHMP's ROE is +0.05%, compared to OSOPF's ROE of +0.21%. Regarding short-term risk, GHMP and OSOPF have similar daily volatility (0.00).Check OSOPF's competition here
GHMP vs PLVFF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, PLVFF has a market cap of 2.1M. Regarding current trading prices, GHMP is priced at $0.00, while PLVFF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas PLVFF's P/E ratio is -1.50. In terms of profitability, GHMP's ROE is +0.05%, compared to PLVFF's ROE of -4.78%. Regarding short-term risk, GHMP and PLVFF have similar daily volatility (0.00).Check PLVFF's competition here
GHMP vs PURT Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, PURT has a market cap of 1.7M. Regarding current trading prices, GHMP is priced at $0.00, while PURT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas PURT's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to PURT's ROE of +0.07%. Regarding short-term risk, GHMP is less volatile compared to PURT. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check PURT's competition here
GHMP vs DRNK Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, DRNK has a market cap of 1.6M. Regarding current trading prices, GHMP is priced at $0.00, while DRNK trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas DRNK's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to DRNK's ROE of -0.16%. Regarding short-term risk, GHMP and DRNK have similar daily volatility (0.00).Check DRNK's competition here
GHMP vs RMHB Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, RMHB has a market cap of 1.4M. Regarding current trading prices, GHMP is priced at $0.00, while RMHB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas RMHB's P/E ratio is -0.24. In terms of profitability, GHMP's ROE is +0.05%, compared to RMHB's ROE of -0.00%. Regarding short-term risk, GHMP is less volatile compared to RMHB. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check RMHB's competition here
GHMP vs ALKM Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, ALKM has a market cap of 864.6K. Regarding current trading prices, GHMP is priced at $0.00, while ALKM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas ALKM's P/E ratio is -0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to ALKM's ROE of -0.17%. Regarding short-term risk, GHMP and ALKM have similar daily volatility (0.00).Check ALKM's competition here
GHMP vs AQPW Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, AQPW has a market cap of 740.9K. Regarding current trading prices, GHMP is priced at $0.00, while AQPW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas AQPW's P/E ratio is -0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to AQPW's ROE of -7.72%. Regarding short-term risk, GHMP and AQPW have similar daily volatility (0.00).Check AQPW's competition here
GHMP vs FMBV Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, FMBV has a market cap of 623.1K. Regarding current trading prices, GHMP is priced at $0.00, while FMBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas FMBV's P/E ratio is -0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to FMBV's ROE of -0.00%. Regarding short-term risk, GHMP and FMBV have similar daily volatility (0.00).Check FMBV's competition here
GHMP vs APRU Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, APRU has a market cap of 591.7K. Regarding current trading prices, GHMP is priced at $0.00, while APRU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas APRU's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to APRU's ROE of +1.02%. Regarding short-term risk, GHMP and APRU have similar daily volatility (0.00).Check APRU's competition here
GHMP vs FBEC Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, FBEC has a market cap of 585.6K. Regarding current trading prices, GHMP is priced at $0.00, while FBEC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas FBEC's P/E ratio is 0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to FBEC's ROE of -0.09%. Regarding short-term risk, GHMP and FBEC have similar daily volatility (0.00).Check FBEC's competition here
GHMP vs ASII Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, ASII has a market cap of 530.7K. Regarding current trading prices, GHMP is priced at $0.00, while ASII trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas ASII's P/E ratio is -0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to ASII's ROE of +0.28%. Regarding short-term risk, GHMP and ASII have similar daily volatility (0.00).Check ASII's competition here
GHMP vs VGID Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, VGID has a market cap of 378.4K. Regarding current trading prices, GHMP is priced at $0.00, while VGID trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas VGID's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to VGID's ROE of +0.00%. Regarding short-term risk, GHMP and VGID have similar daily volatility (0.00).Check VGID's competition here
GHMP vs INKW Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, INKW has a market cap of 328.9K. Regarding current trading prices, GHMP is priced at $0.00, while INKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas INKW's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to INKW's ROE of -0.06%. Regarding short-term risk, GHMP is less volatile compared to INKW. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check INKW's competition here
GHMP vs HFBG Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, HFBG has a market cap of 217.1K. Regarding current trading prices, GHMP is priced at $0.00, while HFBG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas HFBG's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to HFBG's ROE of N/A. Regarding short-term risk, GHMP is less volatile compared to HFBG. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check HFBG's competition here
GHMP vs FHBC Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, FHBC has a market cap of 199.6K. Regarding current trading prices, GHMP is priced at $0.00, while FHBC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas FHBC's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to FHBC's ROE of +0.05%. Regarding short-term risk, GHMP and FHBC have similar daily volatility (0.00).Check FHBC's competition here
GHMP vs DNDT Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, DNDT has a market cap of 184.3K. Regarding current trading prices, GHMP is priced at $0.00, while DNDT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas DNDT's P/E ratio is -0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to DNDT's ROE of +0.02%. Regarding short-term risk, GHMP and DNDT have similar daily volatility (0.00).Check DNDT's competition here
GHMP vs DNAX Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, DNAX has a market cap of 171.8K. Regarding current trading prices, GHMP is priced at $0.00, while DNAX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas DNAX's P/E ratio is 0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to DNAX's ROE of +0.07%. Regarding short-term risk, GHMP and DNAX have similar daily volatility (0.00).Check DNAX's competition here
GHMP vs MLHC Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, MLHC has a market cap of 120K. Regarding current trading prices, GHMP is priced at $0.00, while MLHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas MLHC's P/E ratio is -0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to MLHC's ROE of +0.32%. Regarding short-term risk, GHMP is less volatile compared to MLHC. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check MLHC's competition here
GHMP vs FLWBF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, FLWBF has a market cap of 95.4K. Regarding current trading prices, GHMP is priced at $0.00, while FLWBF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas FLWBF's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to FLWBF's ROE of +0.40%. Regarding short-term risk, GHMP and FLWBF have similar daily volatility (0.00).Check FLWBF's competition here
GHMP vs TBEV Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, TBEV has a market cap of 79.4K. Regarding current trading prices, GHMP is priced at $0.00, while TBEV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas TBEV's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to TBEV's ROE of +1.28%. Regarding short-term risk, GHMP is less volatile compared to TBEV. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check TBEV's competition here
GHMP vs WTER Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, WTER has a market cap of 57.3K. Regarding current trading prices, GHMP is priced at $0.00, while WTER trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas WTER's P/E ratio is -0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to WTER's ROE of +0.78%. Regarding short-term risk, GHMP is less volatile compared to WTER. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check WTER's competition here
GHMP vs HSEEF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, HSEEF has a market cap of 36.1K. Regarding current trading prices, GHMP is priced at $0.00, while HSEEF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas HSEEF's P/E ratio is -0.04. In terms of profitability, GHMP's ROE is +0.05%, compared to HSEEF's ROE of +0.95%. Regarding short-term risk, GHMP is less volatile compared to HSEEF. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check HSEEF's competition here
GHMP vs BBDA Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, BBDA has a market cap of 28.7K. Regarding current trading prices, GHMP is priced at $0.00, while BBDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas BBDA's P/E ratio is 0.01. In terms of profitability, GHMP's ROE is +0.05%, compared to BBDA's ROE of +0.33%. Regarding short-term risk, GHMP is less volatile compared to BBDA. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check BBDA's competition here
GHMP vs NBVG Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, NBVG has a market cap of 25.6K. Regarding current trading prices, GHMP is priced at $0.00, while NBVG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas NBVG's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to NBVG's ROE of -3.18%. Regarding short-term risk, GHMP is less volatile compared to NBVG. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check NBVG's competition here
GHMP vs STZU Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, STZU has a market cap of 22.9K. Regarding current trading prices, GHMP is priced at $0.00, while STZU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas STZU's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to STZU's ROE of N/A. Regarding short-term risk, GHMP is less volatile compared to STZU. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check STZU's competition here
GHMP vs KRED Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, KRED has a market cap of 22.6K. Regarding current trading prices, GHMP is priced at $0.00, while KRED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas KRED's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to KRED's ROE of +3.11%. Regarding short-term risk, GHMP and KRED have similar daily volatility (0.00).Check KRED's competition here
GHMP vs PPBV Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, PPBV has a market cap of 22.5K. Regarding current trading prices, GHMP is priced at $0.00, while PPBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas PPBV's P/E ratio is -0.02. In terms of profitability, GHMP's ROE is +0.05%, compared to PPBV's ROE of -2.55%. Regarding short-term risk, GHMP is less volatile compared to PPBV. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check PPBV's competition here
GHMP vs FGFT Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, FGFT has a market cap of 22.4K. Regarding current trading prices, GHMP is priced at $0.00, while FGFT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas FGFT's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to FGFT's ROE of N/A. Regarding short-term risk, GHMP and FGFT have similar daily volatility (0.00).Check FGFT's competition here
GHMP vs EQLB Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, EQLB has a market cap of 14.3K. Regarding current trading prices, GHMP is priced at $0.00, while EQLB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas EQLB's P/E ratio is -0.03. In terms of profitability, GHMP's ROE is +0.05%, compared to EQLB's ROE of +0.16%. Regarding short-term risk, GHMP is less volatile compared to EQLB. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check EQLB's competition here
GHMP vs BGEM Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, BGEM has a market cap of 12.6K. Regarding current trading prices, GHMP is priced at $0.00, while BGEM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas BGEM's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to BGEM's ROE of -3.20%. Regarding short-term risk, GHMP is less volatile compared to BGEM. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check BGEM's competition here
GHMP vs BVNNF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, BVNNF has a market cap of 12.3K. Regarding current trading prices, GHMP is priced at $0.00, while BVNNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas BVNNF's P/E ratio is -0.00. In terms of profitability, GHMP's ROE is +0.05%, compared to BVNNF's ROE of -7.82%. Regarding short-term risk, GHMP and BVNNF have similar daily volatility (0.00).Check BVNNF's competition here
GHMP vs MCHA Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, MCHA has a market cap of 10.1K. Regarding current trading prices, GHMP is priced at $0.00, while MCHA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas MCHA's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to MCHA's ROE of -0.54%. Regarding short-term risk, GHMP is less volatile compared to MCHA. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check MCHA's competition here
GHMP vs AQUI Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, AQUI has a market cap of 6K. Regarding current trading prices, GHMP is priced at $0.00, while AQUI trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas AQUI's P/E ratio is -0.10. In terms of profitability, GHMP's ROE is +0.05%, compared to AQUI's ROE of +0.00%. Regarding short-term risk, GHMP is less volatile compared to AQUI. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check AQUI's competition here
GHMP vs SWRI Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, SWRI has a market cap of 1.9K. Regarding current trading prices, GHMP is priced at $0.00, while SWRI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas SWRI's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to SWRI's ROE of +0.50%. Regarding short-term risk, GHMP and SWRI have similar daily volatility (0.00).Check SWRI's competition here
GHMP vs HKBV Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, HKBV has a market cap of 1.1K. Regarding current trading prices, GHMP is priced at $0.00, while HKBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas HKBV's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to HKBV's ROE of +0.71%. Regarding short-term risk, GHMP is less volatile compared to HKBV. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check HKBV's competition here
GHMP vs NTEI Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, NTEI has a market cap of 907. Regarding current trading prices, GHMP is priced at $0.00, while NTEI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas NTEI's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to NTEI's ROE of -1.76%. Regarding short-term risk, GHMP is less volatile compared to NTEI. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check NTEI's competition here
GHMP vs ABVG Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, ABVG has a market cap of 31. Regarding current trading prices, GHMP is priced at $0.00, while ABVG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas ABVG's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to ABVG's ROE of -0.07%. Regarding short-term risk, GHMP is less volatile compared to ABVG. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check ABVG's competition here
GHMP vs OSHIF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, OSHIF has a market cap of 0. Regarding current trading prices, GHMP is priced at $0.00, while OSHIF trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas OSHIF's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to OSHIF's ROE of N/A. Regarding short-term risk, GHMP and OSHIF have similar daily volatility (0.00).Check OSHIF's competition here
GHMP vs RMIL Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, RMIL has a market cap of 0. Regarding current trading prices, GHMP is priced at $0.00, while RMIL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas RMIL's P/E ratio is 0.00. In terms of profitability, GHMP's ROE is +0.05%, compared to RMIL's ROE of N/A. Regarding short-term risk, GHMP is less volatile compared to RMIL. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check RMIL's competition here
GHMP vs GGGRF Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, GGGRF has a market cap of 0. Regarding current trading prices, GHMP is priced at $0.00, while GGGRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas GGGRF's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to GGGRF's ROE of N/A. Regarding short-term risk, GHMP and GGGRF have similar daily volatility (0.00).Check GGGRF's competition here
GHMP vs CLCL Comparison June 2026
GHMP plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GHMP stands at 155.5K. In comparison, CLCL has a market cap of 0. Regarding current trading prices, GHMP is priced at $0.00, while CLCL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GHMP currently has a P/E ratio of -0.00, whereas CLCL's P/E ratio is N/A. In terms of profitability, GHMP's ROE is +0.05%, compared to CLCL's ROE of N/A. Regarding short-term risk, GHMP is less volatile compared to CLCL. This indicates potentially lower risk in terms of short-term price fluctuations for GHMP.Check CLCL's competition here